AMPH vs UHS: fair value comparison
Amphastar Pharmaceuticals, Inc. and Universal Health Services, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMPH currently sits closer to the top of our discount ranking. AMPH carries the stronger quality grade.
| AMPH | UHS | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $22.96 | $174.83 |
| 12-month range | $18.42–$27.92 | $144.69–$239.43 |
| Sector rank | #26 of 113 Healthcare | #31 of 113 Healthcare |
| Quality grade | B | C |
| Momentum grade | A | — |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: AMPH fair value analysis · UHS fair value analysis